Monitor upcoming clinical data releases in 2026 for vispa-cel and CB-011, which could be catalysts. Watch for financing activities as the company explores options to fully fund the vispa-cel pivotal trial despite current cash runway into 2H 2027.
Price Chart
Executive Summary
Caribou Biosciences reported its 2025 financial results, showing a slight improvement in net loss despite a $21.3M non-cash impairment charge. The company highlighted positive clinical data for its allogeneic CAR-T therapies vispa-cel and CB-011, with longer-term data expected in 2026. Cash reserves decreased to $142.8M but are expected to fund operations into 2H 2027.
Key Financial Metrics
Key Facts
- Licensing revenue increased to $11.2M in 2025 from $10.0M in 2024
- R&D expenses decreased to $109.4M in 2025 from $130.2M in 2024
- GAAP net loss was $148.1M in 2025 vs $149.1M in 2024
- Non-GAAP net loss improved to $126.8M in 2025 from $149.1M in 2024
- Cash, cash equivalents, and marketable securities decreased to $142.8M from $249.4M
- Company expects current cash to fund operations into 2H 2027
- Presented positive clinical data for vispa-cel and CB-011 at Tandem Meetings
- Engaging with FDA on pivotal trial design for vispa-cel in 2L LBCL
Financial Impact
Net loss decreased by $1M YoY despite $21.3M impairment charge, with cash burn of $106.6M for the year
Risk Factors
- Significant cash burn with $106.6M used in 2025
- Need for additional funding to fully support pivotal trial for vispa-cel
- Clinical trial risks and regulatory approval uncertainties
- Recent insider selling of $47K in the past 30 days
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001619856-26-000007 |
| Document: crbu-20260305.htm | 0001619856-26-000007 |
| Document: 0001619856-26-000007-index-headers.html | 0001619856-26-000007 |
| Document: 0001619856-26-000007-index.html | 0001619856-26-000007 |
| Document: 0001619856-26-000007.txt | 0001619856-26-000007 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 11, 2026 16w ago | 8-K | $1.66 $1.94 | ▲ +16.87% | ▲ +14.98% | $1.23 (−26.20%) |
Jun 11, 2026 16w ago | Press Release | $1.66 $1.94 | ▲ +16.87% | ▲ +14.98% | $1.23 (−26.20%) |
Jun 5, 2026 16w ago | DEFA14A | $1.84 $1.83 | ▼ −0.54% | ▼ −2.17% | $1.23 (−33.42%) |
Apr 24, 2026 22w ago | DEFA14A | $2.13 $2.16 | ▲ +1.41% | ▼ −3.55% | $1.23 (−42.49%) |
Mar 5, 2026 30w ago | 8-K | $1.82 $1.95 | ▲ +7.14% | ▲ +9.19% | $1.23 (−32.69%) |
Mar 5, 2026 30w ago | Press Release | $1.82 $1.95 | ▲ +7.14% | ▲ +9.19% | $1.23 (−32.69%) |
Feb 28, 2026 30w ago | Institutional Cluster | $1.84 $1.72 | ▼ −6.52% | ▲ +1.42% | $1.23 (−33.42%) |
Feb 24, 2026 31w ago | Insider Cluster | $2.14 $1.82 | ▼ −14.95% | ▼ −9.97% | $1.23 (−42.76%) |
Feb 24, 2026 31w ago | Insider Cluster | $2.14 $1.82 | ▼ −14.95% | ▼ −9.97% | $1.23 (−42.76%) |
Feb 24, 2026 31w ago | Insider Cluster | $2.14 $1.82 | ▼ −14.95% | ▼ −9.97% | $1.23 (−42.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access